[go: up one dir, main page]

CR20140219A - POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN - Google Patents

POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN

Info

Publication number
CR20140219A
CR20140219A CR20140219A CR20140219A CR20140219A CR 20140219 A CR20140219 A CR 20140219A CR 20140219 A CR20140219 A CR 20140219A CR 20140219 A CR20140219 A CR 20140219A CR 20140219 A CR20140219 A CR 20140219A
Authority
CR
Costa Rica
Prior art keywords
polymorphes
arry
erbb2
pharmaceutical compositions
compositions containing
Prior art date
Application number
CR20140219A
Other languages
English (en)
Inventor
Donald T Corson
Christopher M Lindemann
Daniel J Watson
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20140219A publication Critical patent/CR20140219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en el presente documento polimorfos de N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina. También se describen procedimientos para preparar los polimorfos y la compo
CR20140219A 2011-10-14 2014-05-12 POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN CR20140219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547615P 2011-10-14 2011-10-14
US201261606185P 2012-03-02 2012-03-02

Publications (1)

Publication Number Publication Date
CR20140219A true CR20140219A (es) 2014-07-11

Family

ID=47471982

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140219A CR20140219A (es) 2011-10-14 2014-05-12 POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN

Country Status (18)

Country Link
US (6) US9168254B2 (es)
EP (1) EP2766363A1 (es)
JP (4) JP2014530243A (es)
KR (2) KR20200003245A (es)
CN (1) CN104011047A (es)
AU (1) AU2012323890A1 (es)
BR (1) BR112014009084B1 (es)
CA (1) CA2852060A1 (es)
CL (1) CL2014000932A1 (es)
CO (1) CO6960548A2 (es)
CR (1) CR20140219A (es)
IL (1) IL232062A0 (es)
MX (2) MX370680B (es)
PH (1) PH12014500809A1 (es)
RU (1) RU2629116C2 (es)
SG (1) SG11201401460PA (es)
UA (1) UA116875C2 (es)
WO (1) WO2013056183A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200003245A (ko) 2011-10-14 2020-01-08 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
DK2765990T3 (da) 2011-10-14 2017-11-13 Array Biopharma Inc Faststofdispersion
TR201808450T4 (tr) 2012-03-23 2018-07-23 Array Biopharma Inc Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon.
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
KR20200012949A (ko) 2017-06-06 2020-02-05 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
PH12021552227A1 (en) 2019-04-02 2022-05-30 Array Biopharma Inc Protein tyrosine phosphatase inhibitors
CA3156820A1 (en) 2019-10-21 2021-04-29 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP2023527794A (ja) 2020-05-29 2023-06-30 シージェン インコーポレイテッド トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法
CA3189333A1 (en) 2020-07-29 2022-02-03 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
MXPA06002963A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
JP5134548B2 (ja) 2005-11-15 2013-01-30 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
KR20200003245A (ko) * 2011-10-14 2020-01-08 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
DK2765990T3 (da) 2011-10-14 2017-11-13 Array Biopharma Inc Faststofdispersion
TR201808450T4 (tr) 2012-03-23 2018-07-23 Array Biopharma Inc Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon.

Also Published As

Publication number Publication date
IL232062A0 (en) 2014-05-28
JP2016033166A (ja) 2016-03-10
KR102061917B1 (ko) 2020-01-02
RU2014119269A (ru) 2015-11-20
EP2766363A1 (en) 2014-08-20
WO2013056183A1 (en) 2013-04-18
US20210077493A1 (en) 2021-03-18
US20140243361A1 (en) 2014-08-28
RU2629116C2 (ru) 2017-08-24
US20180140603A1 (en) 2018-05-24
MX2019010083A (es) 2019-11-21
US10143692B2 (en) 2018-12-04
MX370680B (es) 2019-12-19
UA116875C2 (uk) 2018-05-25
US11571424B2 (en) 2023-02-07
BR112014009084A2 (pt) 2017-05-09
US10765678B2 (en) 2020-09-08
CN104011047A (zh) 2014-08-27
MX2014004553A (es) 2015-02-12
CL2014000932A1 (es) 2014-07-11
CO6960548A2 (es) 2014-05-30
SG11201401460PA (en) 2014-09-26
US20230241066A1 (en) 2023-08-03
JP2014530243A (ja) 2014-11-17
US9168254B2 (en) 2015-10-27
PH12014500809A1 (en) 2014-05-26
US9889134B2 (en) 2018-02-13
BR112014009084B1 (pt) 2021-09-21
KR20140082806A (ko) 2014-07-02
US20160175309A1 (en) 2016-06-23
AU2012323890A1 (en) 2014-05-29
KR20200003245A (ko) 2020-01-08
US20190125749A1 (en) 2019-05-02
CA2852060A1 (en) 2013-04-18
JP2018177822A (ja) 2018-11-15
JP2017128612A (ja) 2017-07-27

Similar Documents

Publication Publication Date Title
CR20140219A (es) POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN
UY39630A (es) Inhibidores de bromodominios
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
GT201400196A (es) Compuestos de heterociclilo
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2016001895A1 (es) Compuestos
CR20140228A (es) Dispersión sólida
GT201300291A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY34264A (es) Compuestos de fórmula genérica 4-(8-metoxi-1-(1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H- imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y sus sales.
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
CL2016000241A1 (es) Formulación de inhibidores de la syk.
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.